Silver Book reference

Survey Results Show that Adults are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs

1 Matching Fact

Search matching Facts:
No results to display
    • The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.